StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) bonds

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$0
Long-term debt
Net debt
-$145.32M
After $145.32M of cash
Implied interest rate
13.14%
FY2025 interest ÷ average debt
Interest coverage
-7.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Zevra Therapeutics's 10-Q for the period ended Mar 12, 2026

IssueCouponAmount issued
Nantahala Note9.00%$5.00M
Term Loans Under Credit AgreementFloating + 7.00%$100.00M
Term Loans Under Credit AgreementFloating + 7.00%$63.10M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?